For research use only. Not for therapeutic Use.
Ridinilazole（Cat No.:I009036）is a novel, targeted antibiotic developed specifically for treating Clostridioides difficile infections (CDI). It works by disrupting bacterial cell division, leading to cell death, and exhibits a narrow-spectrum profile, minimizing impact on beneficial gut microbiota. In research, Ridinilazole is valuable for studying CDI treatment, antibiotic resistance, and microbiome preservation. Its selective action against C. difficile reduces recurrence rates and supports a healthy microbiome, making it a promising candidate in CDI therapy. Ridinilazole’s unique mechanism advances the exploration of targeted approaches to bacterial infections.
| Catalog Number | I009036 |
| CAS Number | 308362-25-6 |
| Synonyms | SMT-19969; SMT 19969; SMT19969; Ridinilazole;2,2/’-di(pyridin-4-yl)-1H,1/’H-5,5/’-bi(benzimidazole) |
| Molecular Formula | C24H16N6 |
| Purity | ≥95% |
| Target | Bacterial |
| Solubility | Soluble in DMSO, not in water |
| Storage | Store at -20°C |
| IUPAC Name | 2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-1H-benzimidazole |
| InChI | InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30) |
| InChIKey | UHQFBTAJFNVZIV-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(N4)C5=CC=NC=C5)NC(=N2)C6=CC=NC=C6 |
| Reference | </br>1:Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; CoDIFy study group..Lancet Infect Dis. 2017 Apr 28. pii: S1473-3099(17)30235-9. doi: 10.1016/S1473-3099(17)30235-9. [Epub ahead of print] PMID: 28461207 Free Article</br>2:Ridinilazole: a novel therapy for Clostridium difficile infection. Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH.Int J Antimicrob Agents. 2016 Aug;48(2):137-43. doi: 10.1016/j.ijantimicag.2016.04.026. Epub 2016 May 30. Review. PMID: 27283730 Free Article</br>3:Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. Bassères E, Endres BT, Khaleduzzaman M, Miraftabi F, Alam MJ, Vickers RJ, Garey KW.J Antimicrob Chemother. 2016 May;71(5):1245-51. doi: 10.1093/jac/dkv498. Epub 2016 Feb 18. PMID: 26895772 Free PMC Article |
